Expanding Global Presence CardioSignal has recently entered the US market and established key partnerships with companies like Jisekihealth and OMRON Healthcare, demonstrating a strong commitment to remote cardiac care solutions and opening opportunities to collaborate with healthcare providers and device manufacturers in new markets.

Secured Series A Funding With a recent $10 million Series A investment led by DigiTx Partners, CardioSignal has increased resources for product development and scaling efforts, presenting a prime opportunity to engage with healthcare institutions, insurance firms, and investors interested in innovative heart disease detection technology.

Innovative Technology Platform Built on a decade of research with CE-marked device hardware and proprietary algorithms, CardioSignal offers advanced digital biomarkers for atrial fibrillation and other heart diseases, enabling partnerships with medical device companies and telehealth platforms seeking reliable, groundbreaking diagnostic solutions.

Strategic Industry Collaborations Partnerships with leading firms like OMRON Healthcare and Jisekihealth highlight opportunities to integrate CardioSignal's technology into existing remote monitoring systems, expanding sales channels to healthcare providers and device distributors focusing on cardiovascular care.

Focus on Early Detection CardioSignal's mission to support early diagnosis of heart conditions aligns with a growing market demand for preventive healthcare solutions, making it an attractive partner for organizations aiming to enhance their remote monitoring and chronic disease management offerings.